13:09 , Jun 8, 2018 |  BC Extra  |  Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing Friday, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS representing...
22:57 , Nov 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: T cell lymphoma; leukemia Patient sample and mouse studies suggest chimeric antigen receptor (CAR) T cells targeting TRBC1 could help treat TRBC1-positive T cell lymphomas and T cell leukemias. In cultures of T cells from...
19:51 , Nov 13, 2017 |  BC Extra  |  Preclinical News

UCL, Autolus develop CARs against T cell malignancies that partially preserve normal T cells

A Nature Medicine study published Monday describes a chimeric antigen receptor (CAR)-based strategy to target T cell malignancies without wiping out normal T cells. Autolus Ltd. (London, U.K.) licensed the technology from University College London. CAR...